Valiance Asset Management Founded 2008
Founders
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 5
Average round size
info
The average size of a deal this fund participated in
$14M
Portfolio companies 5
Rounds per year 0.38
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits -
Key employees -
Stages of investment
Late Stage Venture
Latest deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
FEops
Biotechnology
Health Care
Medical
Medical Device
Simulation
Series B
6M19 Apr 2021 Belgium, Ghent
MyoScience
Biotechnology
Pharmaceutical
Therapeutics
Series E
25M19 Apr 2021 United States, Redwood City
MDxHealth
Biotechnology
Health Diagnostics
Medical Device
Post-IPO Equity
23M19 Apr 2021 United States, Irvine
MyoScience
Biotechnology
Pharmaceutical
Therapeutics
Venture - Series Unknown
10M19 Apr 2021 United States, Redwood City
JenaValve Technology
Health Care
Medical
Medical Device
Series C
10M19 Apr 2021 Germany, Munich
NeoSync
Clinical Trials
Information Technology
Medical
Series D
13M10 Aug 2017 United States, South Boston
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Valiance Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: